Quantcast

Latest Adenoviridae Stories

2011-07-13 09:00:00

Durham, N.C., July 13, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that patient dosing has begun in the AdV HALT Trial (A Randomized, Placebo-Controlled, Multi-site Phase 2 Study Evaluating the Safety and Efficacy of Preemptive Treatment with CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation [HSCT]).The company also announced that the U.S. Food and Drug...

2011-06-27 23:12:24

And other neurological disorders highlighted in Human Gene Therapy Novel tools and methods for delivering therapeutic genes to cells in the central nervous system hold great promise for the development of new treatments to combat incurable neurologic diseases. Five of the most exciting developments in this rapidly advancing field are presented in a series of articles in the June issue of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The...

2011-05-11 12:46:00

DURHAM, N.C., May 11, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing oral antiviral therapeutics, today presented data showing that the majority of immunocompromised patients with severe adenovirus infections who were treated with Chimerix's lead antiviral compound, CMX001, had a > 99% decrease in viral load compared to baseline after two weeks of therapy. These CMX001 clinical data, described in an oral presentation today at the 24th Annual International...

2011-04-02 01:52:43

Early data from phase I trials of an HCV vaccine presented today at the International Liver CongressTM show encouraging results, with high immunogenicity and good safety profile. In the first study1, a therapeutic T-cell vaccine, based on novel adenoviral vectors was used on a small population of treatment naive patients with chronic genotype 1 HCV infection. Intra-muscular vaccination was administered 2 or 14 weeks into a 48-week course of treatment with Peg-IFNa2a/ribavirin. 50% of...

2011-03-25 08:24:00

DURHAM, N.C., March 25, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at two upcoming investor conferences in New York City: the Needham & Company 10th Annual Health Care Conference on April 6, 2011 at 8:40am ET at The New York Palace Hotel, and at the BioCentury/Thomson Reuters 18th Annual...

2011-03-01 08:00:00

DURHAM, N.C., March 1, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at the Cowen and Company 31st Annual Health Care Conference on March 8, 2011, 1:30 pm ET, at the Boston Marriott Copley Place in Boston, Massachusetts. The Cowen and Company Health Care Conference is a conference for institutional...

2011-02-24 08:30:00

DURHAM, N.C., Feb. 24, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of the first reported case in which adenovirus (AdV) infection was successfully eradicated following treatment with its broad-spectrum antiviral drug, CMX001. Oral CMX001 was administered under an Emergency Investigational New Drug Application (EIND) to a severely immunocompromised pediatric stem cell patient following...

2011-02-24 07:30:00

DURHAM, N.C., Feb. 24, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at the Citi 2011 Global Health Care Conference on March 1, 2011 at 3:00 p.m. ET at the Hilton New York Hotel in New York City, NY. Mr. Moch will give an update on the company's pipeline and technology assets, including CMX001, a...

2011-02-14 07:30:00

DURHAM, N.C., Feb. 14, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available broad spectrum antiviral therapeutics, today announced the completion of a $45 million Series F financing. New Leaf Venture Partners led the round, with participation by new investors Pappas Ventures and Morningside Group, as well as existing investors Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Company and Frazier Healthcare Ventures. Proceeds from...

2011-01-24 04:42:00

ORLANDO, Florida, January 24, 2011 /PRNewswire/ -- The Canine VacciCheck was discussed during a panel discussion in a vaccination symposium at the NAVC. During this panel discussion, a question was raised as to the options available regarding checking for titers for the core vaccines of Hepatitis, Parvovirus and Distemper. Professor Ronald Schultz from the University of Wisconsin mentioned the Canine VacciCheck as a novel "in house" option for titer checking. Professor Schultz...


Latest Adenoviridae Reference Libraries

0_f9fe10c6664d20ba0d9091907b66a65f
2011-01-05 16:00:36

Human parainfluenza viruses, belonging to the paramyxovirus family, are a group of four distinct serotypes of enveloped single-stranded RNA viruses. They are the second most common cause of lower respiratory tract infection in younger children. Many times the host has repeat infections throughout life with symptoms that may include upper respiratory tract illness or more commonly, a cold and sore throat. It can also cause severe pneumonia in immunosuppressed people. There is currently no...

More Articles (1 articles) »
Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related